Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines
The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
The gradual loss of DNA from the ends of telomeres has been implicated in the control of cellular proliferative potential. Telomerase is an enzyme that restores telomeric DNA sequences, and expression of its activity was thought to be essential for the immortalization of human cells, both in vitro and in tumor progression in vivo. Telomerase activity has been detected in 50-100% of tumors of different types, but not in most normal adult somatic tissues. It has also been detected in about 70% of human cell lines immortalized in vitro and in all tumor-derived cell lines examined to date. It has previously been shown that in vitro immortalized telomerase-negative cell lines acquire very long and heterogeneous telomeres in association with immortalization presumably via one or more novel telomere-lengthening mechanisms that we refer to as ALT (alternative lengthening of telomeres). Here we report evidence for the presence of ALT in a subset of tumor-derived cell lines and tumors. The maintenance of telomeres by a mechanism other than telomerase, even in a minority of cancers, has major implications for therapeutic uses of telomerase inhibitors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“a few rare tumors (29) and some experimentally immortalized cell lines (30) lack detectable telomerase activity.”
From Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death (1999) · cites this paper as [30]
In the citing paper
“Virally transformed human cells that eliminate p53 and/or pRB function can escape crisis at very low frequencies, and invariably adopt telomere-maintenance programs: 80-90% of human tumors possess some telomerase activity, while the remainder maintain telomeres via a recombination-mediated process termed ALT (for Alternative Lengthening of Telomeres)37-40.”
From Telomere dysfunction and tumour suppression: the senescence connection (2008) · cites this paper as [39]
In the citing paper
“A significant number of human tumours can also maintain telomeres by recombination-based ALT mechanisms in the absence of telomerase 72 .”
From The common biology of cancer and ageing (2007) · cites this paper as [72]
Citations
Cites
Specific Association of Human Telomerase Activity with Immortal Cells and Cancer
Kim, N. W., Piatyszek, M. A., Prowse, K. R., Harley, C. B., West, M. D., Ho, P. L. C., Coviello, G. M., Wright, W. E., Weinrich, S. L., & Shay, J. W. (1994) · Science · doi:10.1126/science.7605428 · Cited by 7,091
Telomeres shorten during ageing of human fibroblasts
Harley, C. B., Futcher, A. B., & Greider, C. W. (1990) · Nature · doi:10.1038/345458a0 · Cited by 5,750
The p53 tumour suppressor gene
Levine, A. J., Momand, J., & Finlay, C. A. (1991) · Nature · doi:10.1038/351453a0 · Cited by 3,788
Identification of a specific telomere terminal transferase activity in tetrahymena extracts
Greider, C. W., & Blackburn, E. H. (1985) · Cell · doi:10.1016/0092-8674(85)90170-9 · Cited by 3,400
Counter, C. M., Avilion, A. A., LeFeuvre, C. E., Stewart, N. G., Greider, C. W., Harley, C. B., & Bacchetti, S. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05245.x · Cited by 2,096
Telomere reduction in human colorectal carcinoma and with ageing
Hastie, N. D., Dempster, M., Dunlop, M. G., Thompson, A. M., Green, D. K., & Allshire, R. C. (1990) · Nature · doi:10.1038/346866a0 · Cited by 1,650
Telomere elongation in immortal human cells without detectable telomerase activity
Bryan, T. M., Englezou, A., Gupta, J., Bacchetti, S., & Reddel, R. R. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb00098.x · Cited by 1,279
Self-citationTelomere loss: mitotic clock or genetic time bomb?
Harley, C. B. (1991) · Mutation Research/DNAging · doi:10.1016/0921-8734(91)90018-7 · Cited by 1,139
An alternative pathway for yeast telomere maintenance rescues est1− senescence
Lundblad, V., & Blackburn, E. H. (1993) · Cell · doi:10.1016/0092-8674(93)90234-h · Cited by 942
Telomerase activity in human ovarian carcinoma.
Counter, C. M., Hirte, H. W., Bacchetti, S., & Harley, C. B. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.8.2900 · Cited by 677
Cited by
Items 501–600 of 1,000
Zaffaroni, N., Lualdi, S., Villa, R., Bellarosa, D., Cermele, C., Felicetti, P., Rossi, C., Orlandi, L., & Daidone, M. G. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00139-9 · Cited by 41
“It has previously been shown that some human tumours exhibit both telomere maintenance mechanisms [45].”
BackgroundTwo roles for Rad50 in telomere maintenance
Vannier, J., Depeiges, A., White, C. I., & Gallego, M. E. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601345 · Cited by 41
“…the same mechanism as that proposed for the recombination-mediated (ALT) lengthening of telomeres in the absence of telomerase in animals (Bryan et al, 1995, 1997; Bailey et al, 2004; Londono-Vallejo et al, 2004) (review by Muntoni and Reddel, 2005) and similar to that of Rad50dependent…”
BackgroundNatarajan, S., Groff-Vindman, C., & McEachern, M. J. (2003) · Eukaryotic Cell · doi:10.1128/ec.2.5.1115-1127.2003 · Cited by 44
“There has been recent evidence that ALT in mammalian cells is dependent on homologous recombination (2, 7, 9).”
BackgroundTelomerase and c-myc expression in hepatocellular carcinomas
Liu, Y., Chen, C., Wu, H., Chan, D., Yu, J.-C., Yang, A., Cheng, Y.-L., Lee, S.-C., & Harn, H. (2004) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2004.01.003 · Cited by 41
Telomerase inhibitors: targeting the vulnerable end of cancer?
Kèlland, L. R. (2000) · Anti-Cancer Drugs · doi:10.1097/00001813-200008000-00001 · Cited by 43
Tseng, S., Shen, Z.-J., Tsai, H.-J., Lin, Y., & Teng, S. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp235 · Cited by 43
Telomerase inhibition and the future management of head-and-neck cancer
McCaul, J. A., Gordon, K., Clark, L., & Parkinson, E. K. (2002) · The Lancet Oncology · doi:10.1016/s1470-2045(02)00729-5 · Cited by 44
PCNA cycling dynamics during DNA replication and repair in mammals
Kang, S., Yoo, J., & Myung, K. (2024) · Trends in Genetics · doi:10.1016/j.tig.2024.02.006 · Cited by 45
Slatter, T. L., Gifford-Garner, J., Wiles, A. K., Tan, X., Chen, Y.-J., MacFarlane, M. R., Sullivan, M. J., Royds, J. A., & Hung, N. A. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.100468 · Cited by 39
Porreca, R. M., Herrera‐Moyano, E., Skourti, E., Law, P. P., Gonzalez-Franco, R., Montoya, A., Faull, P. A., Kramer, H., & Vannier, J. (2020) · eLife · doi:10.7554/elife.49817 · Cited by 39
“The majority of cancer cells reactivate telomerase, while a minority (10– 15%) uses an alternative mechanism named ALT for alternative lengthening of telomeres (Bryan et al., 1997; Kim et al., 1994).”
BackgroundPersistent telomere cohesion protects aged cells from premature senescence
Azarm, K., Bhardwaj, A., Kim, E., & Smith, S. (2020) · Nature Communications · doi:10.1038/s41467-020-17133-4 · Cited by 35
Ackerson, S. M., Romney, C. V., Schuck, P. L., & Stewart, J. A. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.708763 · Cited by 45
Applications of telomerase research in the fight against cancer
McKenzie, K. E., Umbricht, C. B., & Sukumar, S. V. (1999) · Molecular Medicine Today · doi:10.1016/s1357-4310(98)01429-4 · Cited by 51
Yamamoto, A., Kumakura, S., Uchida, M., Barrett, J. C., & Tsutsui, T. (2003) · International Journal of Cancer · doi:10.1002/ijc.11219 · Cited by 38
Breaking new ground: Digging into TERRA function
Maicher, A., Lockhart, A., & Luke, B. (2014) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2014.03.012 · Cited by 43
Diagnosis and treatment of ALT tumors: is Trabectedin a new therapeutic option?
Pompili, L., Leonetti, C., Biroccio, A., & Salvati, E. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0657-3 · Cited by 42
“In a limited subset of tumors, telomere length is restored by activation of alternative mechanisms (ALT) [10, 11] involving homologous recombination (HR) and homology directed telomere synthesis, preferentially occurring at lagging strand, leading to heterogeneous telomere length observed in most ALT cells [12].”
Telomeres and anthropogenic disturbances in wildlife: A systematic review and meta‐analysis
Salmón, P., & Burraco, P. (2022) · Molecular Ecology · doi:10.1111/mec.16370 · Cited by 41
New twists to the ALTernative endings at telomeres
Bhargava, R., Lynskey, M. L., & O’Sullivan, R. J. (2022) · DNA repair · doi:10.1016/j.dnarep.2022.103342 · Cited by 41
Unwinding protein complexes in ALTernative telomere maintenance
Bhattacharyya, S., Sandy, A., & Groden, J. L. (2009) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22388 · Cited by 44
“In other human tumors, immortalized human cell lines and telomerase-null mouse cell lines [Bryan et al., 1995, 1997; Hande et al., 1999; Niida et al., 2000], telomere lengths are maintained through many population doublings (PDs) using one or more non-telomerase mechanisms known as Alternative…”
BackgroundZaffaroni, N., Villa, R., Pastorino, U., Cirincione, R., Incarbone, M., Alloisio, M., Curto, M., Pilotti, S., & Daidone, M. G. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1293 · Cited by 41
FAM111A induces nuclear dysfunction in disease and viral restriction
Nie, M., Oravcová, M., Jami‐Alahmadi, Y., Wohlschlegel, J. A., Denchi, E. L., & Boddy, M. N. (2020) · EMBO Reports · doi:10.15252/embr.202050803 · Cited by 42
“A key difference is that U2OS cells maintain their telomeres via a recombination-based replication process called alternative lengthening of telomeres (ALT), as they do not have active telomerase (Bryan et al , 1997; Cesare & Reddel, 2010).”
The Power of Stress: The Telo-Hormesis Hypothesis
Burbano, M. S. J., & Gilson, É. (2021) · Cells · doi:10.3390/cells10051156 · Cited by 41
“Interestingly, eukaryotic cells are able to use a telomerase-independent mechanism, ALT (alternative lengthening of telomeres), which is based on homologous recombination [30].”
BackgroundTelomeres in cancer and aging: lessons from the mouse
Blasco, M. A. (2003) · Cancer Letters · doi:10.1016/s0304-3835(02)00705-x · Cited by 40
Iyer, S., Chadha, A. D., & McEachern, M. J. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.18.8064-8073.2005 · Cited by 36
“of alternative lengthening of telomeres (ALT) (7).”
Liu, L., Berletch, J. B., Green, J. G., Pate, M. S., Andrews, L. G., & Tollefsbol, T. O. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1003.3.8 · Cited by 38
“Although alternative mechanisms of maintaining telomere length have been reported (8),”
BackgroundTaylor, L. M., James, A., Schuller, C. E., Brce, J., Lock, R. B., & MacKenzie, K. L. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m402388200 · Cited by 36
Telomere length and telomerase activity in canine mammary gland tumors
Yazawa, M., Okuda, M., Setoguchi, A., Iwabuchi, S., Nishimura, R., Sasaki, N., Masuda, K., Ohno, K., & Tsujimoto, H. (2001) · American Journal of Veterinary Research · doi:10.2460/ajvr.2001.62.1539 · Cited by 41
Telomere Dynamics in a Human Cancer Cell Line
Sprung, C. N., Sabatier, L., & Murnane, J. P. (1999) · Experimental Cell Research · doi:10.1006/excr.1998.4293 · Cited by 37
Oh, B., Um, T.-H., Choi, G. H., & Park, Y. N. (2010) · International Journal of Cancer · doi:10.1002/ijc.25398 · Cited by 36
Telomerase and Telomeres in Endometrial Cancer
Alnafakh, R., Adishesh, M., Button, L., Saretzki, G. C., & Hapangama, D. K. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00344 · Cited by 64
“Telomere Maintenance by Alternative Lengthening of Telomeres (ALT) Cells can maintain their telomeres via a telomerase dependent pathway or a telomerase independent ALT pathway (69).”
BackgroundDrivers underpinning the malignant transformation of giant cell tumour of bone
Fittall, M. W., Lyskjær, I., Ellery, P., Lombard, P., Ijaz, J., Strobl, A., Oukrif, D., Tarabichi, M., Sill, M., Koelsche, C., et al. (2020) · The Journal of Pathology · doi:10.1002/path.5537 · Cited by 37
“Two other malignant samples, PD4922e and PD30985a, were identified as having markedly elongated telomeres (Figure 1B and supplementary material, Figure S1), a finding consistent with alternative lengthening of telomeres (ALT) pathway activation, which is usually mutually exclusive with TERT alteration [15,16].”
ResultThe Molecular Mechanisms and Therapeutic Prospects of Alternative Lengthening of Telomeres (ALT)
Sohn, E. J., Goralsky, J. A., Shay, J. W., & Min, J. (2023) · Cancers · doi:10.3390/cancers15071945 · Cited by 43
“ALT activation was found to be dependent on TERRA transcription [45].”
BackgroundCheng, C., Shtessel, L., Brady, M., & Ahmed, S. C. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119191109 · Cited by 36
Feng, X., Luo, Z., Jiang, S., Li, F., Han, X., Hu, Y., Wang, D., Zhao, Y. B., Ma, W., Liu, D., et al. (2013) · Journal of Cell Science · doi:10.1242/jcs.128512 · Cited by 45
“The remaining 10–15% of cancer cells, predominantly mesenchymal or neuroepithelial precursors, appear to extend their telomeres through alternative lengthening of telomeres (ALT), a mechanism that depends on homologous recombination (HR) rather than the telomerase (Bryan et al., 1997; Cesare and Reddel, 2010; Heaphy e…”
BackgroundSporadic colorectal adenocarcinomas with high‐frequency microsatellite instability
Gafà, R., Maestri, I., Matteuzzi, M., Santini, A., Ferretti, S., Cavazzini, L., & Lanza, G. (2000) · Cancer · doi:10.1002/1097-0142(20001115)89:10<2025::aid-cncr1>3.3.co;2-j · Cited by 216
A mouse model of Werner Syndrome: what can it tell us about aging and cancer?
Chang, S. S. (2004) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2004.11.007 · Cited by 41
Reversible Conversion of Immortal Human Cells from Telomerase-Positive to Telomerase-Negative Cells
Kumakura, S., Tsutsui, T. W., Yagisawa, J., Barrett, J. C., & Tsutsui, T. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-1819 · Cited by 35
“Lanes (3 ) or (4), genomic DNAs from E6 Cl 6 at 428 PD or KMST-6, respectively, digested with Bal 31 for 0 to 60 minutes followed by Hin fI.”
MethodDetection of malignant effusions: Comparison of a telomerase assay and cytologic examination
Braunschweig, R., Yan, P., Guilleret, I., Delacrétaz, F., Bosman, F. T., Mihaescu, A., & Benhattar, J. (2001) · Diagnostic Cytopathology · doi:10.1002/1097-0339(200103)24:3<174::aid-dc1036>3.0.co;2-8 · Cited by 35
TRF1 is a critical trans-acting factor required for de novo telomere formation in human cells
Okabe, J., Eguchi, A., Masago, A., Hayakawa, T., & Nakanishi, M. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.18.2639 · Cited by 37
“Furthermore, ∼30% of immortal human cells have no detectable telomerase activity (19,20).”
BackgroundZaffaroni, N., Porta, C. D., Villa, R., Botti, C., Buglioni, S., Mottolese, M., & Daidone, M. G. (2002) · The Journal of Pathology · doi:10.1002/path.1178 · Cited by 40
“The results also suggest the possibility that these breast carcinomas express the ALT (alternative lengthening of telomeres) mechanisms, which are responsible for the maintenance of telomeres — probably through recombination events [36] — and have been demonstrated to be present in a minority of tumours [37].”
BackgroundScheers, I., Lombard, C. A., Paganelli, M., Campard, D., Najimi, M., Gala, J., Decottignies, A., & Sokal, E. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071374 · Cited by 36
“The second mechanism relies on telomeric DNA recombination for telomere maintenance and is detected mostly in sarcomas and in vitro SV40immortalized fibroblasts [54].”
BackgroundTargeting human telomerase for cancer therapeutics
Guittat, L., Alberti, P., Gómez, D., Cian, A. D., Pennarun, G., Lemarteleur, T., Belmokhtar, C., Boujemaa‐Paterski, R., Morjani, H., Trentesaux, C., et al. (2004) · Cytotechnology · doi:10.1007/s10616-004-5127-z · Cited by 39
“%) lack telomerase activity and can maintain telomeres through telomerase-independent mechanism (Bryan et al. 1995, 1997; Dunham et al. 2000; Hoare et al. 2001; Reddel 2003).”
BackgroundBoyd, M., Mairs, R. J., Mairs, S. C., Wilson, L., Livingstone, A., Cunningham, S. H., Brown, M. M., Nicol, M. Q., & Keith, W. N. (2001) · Oncogene · doi:10.1038/sj.onc.1204955 · Cited by 34
“Furthermore, it has recently been documented that some tumour cells have the capacity to maintain telomeres despite the absence of telomerase expression (Bryan et al., 1997).”
BackgroundTargeting the Molecular and Immunologic Features of Leiomyosarcoma
Cope, B. M., Traweek, R. S., Lazcano, R., Keung, E. Z.-Y., Lazar, A. J., Roland, C. L., & Nassif, E. F. (2023) · Cancers · doi:10.3390/cancers15072099 · Cited by 37
“Alternative lengthening of telomeres (ALT) is a telomerase-independent mechanism by which cancerous cells of typically mesenchymal origin achieve replicative immortality [123,124].”
BackgroundTelomeropathies: Etiology, diagnosis, treatment and follow‐up. Ethical and legal considerations
Armando, R. G., Gómez, D. L. M., Maggio, J., Sanmartin, M. C., & Gomez, D. E. (2019) · Clinical Genetics · doi:10.1111/cge.13526 · Cited by 35
Z-flipon variants reveal the many roles of Z-DNA and Z-RNA in health and disease
Umerenkov, D., Herbert, A. G., Konovalov, D., Danilova, A., Beknazarov, N., Kokh, V., Fedorov, A., & Poptsova, M. S. (2023) · Life Science Alliance · doi:10.26508/lsa.202301962 · Cited by 40
Synergy Between 3′Azido-3′deoxythymidine and Paclitaxel in Human Pharynx FaDu Cells
Johnston, J. S., Johnson, A. D., Gan, Y., Wientjes, M. G., & Au, J. L. ‐. (2003) · Pharmaceutical Research · doi:10.1023/a:1024431218327 · Cited by 36
“The long lag time may also allow for activation of the telomerase-independent alternative mechanism of telomere maintenance (9).”
BackgroundRitz, J. M., Kühle, O., Riethdorf, S., Sipos, B., Deppert, W., Englert, C., & Güneş, Ç. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3046 · Cited by 39
Graham, M. K., Kim, J. Y., Da, J., Brosnan‐Cashman, J. A., Rizzo, A. J., Valle, J. A. B.-D., Chia, L., Rubenstein, M., Davis, C., Zheng, Q., et al. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0654 · Cited by 35
“AbolishingATRXdoesnotdisrupt telomerase activity in LAPC-4 and CWR22Rv1 Themajority of telomerase-deficient cancers rely exclusively on ALT for telomere maintenance (9).”
BackgroundSfeir, A. J. (2012) · Journal of Cell Science · doi:10.1242/jcs.106831 · Cited by 45
“…of HDR by RAP1, POT1 and the Ku70–Ku80 complex HDR is typically repressed at telomeres, but occurs in a small subset of tumors that do not use telomerase for telomere maintenance (Bryan et al., 1997) as well as during the early cleavage cycles during embryonic development (Liu et al., 2007).”
BackgroundTelomere Length Changes in Colorectal Cancers and Polyps
Kim, H. R., Kim, Y. J., Kim, H. J., Kim, S. K., & Lee, J. H. (2002) · Journal of Korean Medical Science · doi:10.3346/jkms.2002.17.3.360 · Cited by 32
“However, it has been reported that some human tumors and some tumor-derived cell lines display telomere elongation in the apparent absence of telomerase activity (27, 30).”
BackgroundKepkay, R., Attwood, K. M., Ziv, Y., Shiloh, Y., & Dellaire, G. (2011) · Cell Cycle · doi:10.4161/cc.10.2.14551 · Cited by 33
Chen, W., Qin, L., Wang, S., Li, M., Shi, D., Tian, Y., Wang, J., Fu, L., Li, Z., Guo, W., et al. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.02.001 · Cited by 33
Su, X., Jiang, X., Wang, W., Wang, H., Xu, X., Lin, A., Teng, X., Wu, H., & Teng, L. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s116594 · Cited by 34
Daniloski, Z., & Smith, S. H. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1260 · Cited by 35
“Hallmark features of ALT cells include the loss of ATRX and DAXX expression (34,35), the presence of ALT-associated promyelocytic leukemia (PML) bodies (APBs) (36) and partially single-stranded telomeric extrachromosomal (CCCTAA) DNA circles (C-circles) (27), and the absence of telomerase activity (37).”
Riethdorf, S., Riethdorf, L., Schulz, G., Ikenberg, H., nicke, F. J. A., ning, T. L., & Park, T. (2001) · International Journal of Gynecological Pathology · doi:10.1097/00004347-200104000-00011 · Cited by 34
Modeling aging and cancer in the telomerase knockout mouse
Chang, S. S. (2005) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2004.08.020 · Cited by 38
Dalerba, P. D., Guiducci, C., Poliani, P. L., Cifola, I., Parenza, M., Frattini, M., Gallino, G., Carnevali, I. W., Giulio, I. D., Andreola, S. A., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3678 · Cited by 36
“alternative mechanisms, known together as alternative lengthening of telomeres (ALT) and presumably based on telomere recombination (7, 8).”
BackgroundThe telomerase cycle: normal and pathological aspects
Brunori, M., Luciano, P., Gilson, É., & G�li, V. (2005) · Journal of Molecular Medicine · doi:10.1007/s00109-004-0616-2 · Cited by 33
“APBs are nuclear structures considered as essential components of the telomere maintenancemachinery in ALTcells [134].”
BackgroundInfluentialGastroenteropancreatic endocrine tumors
Meeker, A. K., & Heaphy, C. M. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.07.015 · Cited by 34
“In order to evaluate the timing of ATRX and DAXX mutations during PanNET tumorigenesis and progression, de Wilde and colleagues assessed ATRX or DAXX nuclear protein expression and ALT status in tissues obtained from a cohort of MEN1 syndrome patients (de Wilde et al., 2012b).”
BackgroundInfluentialNovakovic, B., Evain‐Brion, D., Murthi, P., Fournier, T., & Saffery, R. (2017) · The FASEB Journal · doi:10.1096/fj.201601189rr · Cited by 33
“This is also associated with up-regulation of the TERRA transcript and loss of methylation at TERRA promoters (52); however, the specific role of differential DAXX expression in this process requires further investigation.”
BackgroundEpigenetic Regulation of Telomere Maintenance for Therapeutic Interventions in Gliomas
Naderlinger, E., & Holzmann, K. (2017) · Genes · doi:10.3390/genes8050145 · Cited by 37
Telomeres in toxicology: Occupational health
Shoeb, M., Meier, H. C. S., & Antonini, J. M. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107742 · Cited by 33
Aguilar, M. R., & Prieto, P. (2021) · Frontiers in Plant Science · doi:10.3389/fpls.2021.672489 · Cited by 34
Tieing together loose ends: telomere instability in cancer and aging
Borges, G. D. O., Criqui, M., & Harrington, L. A. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13299 · Cited by 37
Miracco, C., Santi, M. M. D., Schürfeld, K., Santopietro, R., Lalinga, A. V., Fimiani, M., BIAGIOLI, M., Brogi, M., Felice, C. D., Luzi, P., et al. (2002) · British Journal of Dermatology · doi:10.1046/j.1365-2133.2002.04600.x · Cited by 33
p53 Differentially Inhibits Cell Growth Depending on the Mechanism of Telomere Maintenance
Razak, Z. R. A., Varkonyi, R. J., McEliece, M. K., Caslini, C., Testa, J. R., Murphy, M. E., & Broccoli, D. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.13.5967-5977.2004 · Cited by 34
“While most tumors achieve telomere stabilization through the activation of telomerase (48), a subset of tumors utilize a telomerase-independent mechanism termed alternative lengthening of telomeres (ALT) to maintain chromosome termini (7, 8).”
BackgroundRegulation of Telomere Homeostasis during Epstein-Barr virus Infection and Immortalization
Kamranvar, S. A., & Masucci, M. G. (2017) · Viruses · doi:10.3390/v9080217 · Cited by 31
“Cancers that lack telomerase activity exploit a DNA repair-based mechanism for telomere elongation referred to as ALT [52].”
BackgroundTurkalo, T. K., Maffia, A., Schabort, J. J., Regalado, S. G., Bhakta, M. S., Blanchette, M., Spierings, D. C. J., Lansdorp, P. M., & Hockemeyer, D. F. (2023) · Nature Communications · doi:10.1038/s41467-023-36294-6 · Cited by 32
Hu, Y., Bobb, D., He, J., Hill, D. A., & Dome, J. S. (2015) · Cancer Biology & Therapy · doi:10.1080/15384047.2015.1040964 · Cited by 33
“It is also possible that osteosarcoma cells could activate the alternative lengthening of telomeres (ALT) pathway as a resistance mechanism.(31,32) ALT is of particular interest in osteosarcoma because up to 50% of human osteosarcoma tumors use ALT, rather than telomerase, to maintain telomeres.”
PML is required for telomere stability in non-neoplastic human cells
Marchesini, M., Matocci, R., Tasselli, L., Cambiaghi, V., Orleth, A., Furia, L., Marinelli, C., Lombardi, S., Sammarelli, G., Aversa, F., et al. (2015) · Oncogene · doi:10.1038/onc.2015.246 · Cited by 31
Activation of p53 protein by telomeric (TTAGGG)n repeats
Milyavsky, M., Mimran, A., Senderovich, S., Zurer, I., Erez, N., Shats, I., Goldfinger, N., Cohen, I., & Rotter, V. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.24.5207 · Cited by 33
“The second pathway, alternative lengthening of telomeres (ALT), is a less frequently used mechanism based on recombination (46,47).”
BackgroundGenetic Architecture of Natural Variation of Telomere Length in Arabidopsis thaliana
Fulcher, N., Teubenbacher, A., Kerdaffrec, E., Farlow, A., Nordborg, M., & Říha, K. (2014) · Genetics · doi:10.1534/genetics.114.172163 · Cited by 37
“Telomeres can also be elongated under certain conditions by homologous recombination-based mechanisms collectively known as “alternative lengthening of telomeres” (Bryan et al. 1997).”
BackgroundCerone, M. A., Londoño‐Vallejo, A., & Autexier, C. (2006) · Oncogene · doi:10.1038/sj.onc.1209727 · Cited by 36
“…hTR increases drug sensitivity in immortal cells that maintain telomeres via the ALT pathway A total of 10–15% of human tumors do not rely on telomerase for telomere maintenance but use an Oncogene alternative mechanism most likely based on recombination (Bryan et al., 1997; Dunham et al., 2000).”
BackgroundButylidenephthalide Suppresses Human Telomerase Reverse Transcriptase (TERT) in Human Glioblastomas
Lin, P., Lin, S., Chen, Y.-L., Chang, J., Ho, L.-I., Liu, P.-Y., Chang, L.-F., Harn, Y., Chen, S., Sun, L., et al. (2011) · Annals of Surgical Oncology · doi:10.1245/s10434-011-1644-0 · Cited by 32
“On the other hand, tumors lacking telomerase activity maintain telomeres by a recombination-mediated process termed alternative lengthening of telomeres.(12) In most cancers, the level of”
BackgroundTelomere-Maintenance Mechanisms in Soft-Tissue Malignant Fibrous Histiocytomas
Matsuo, T., Shay, J. W., Wright, W. E., Hiyama, E., Shimose, S., Kubo, T., Sugita, T., Yasunaga, Y., & Ochi, M. (2009) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.g.01390 · Cited by 35
Leben am Ende der Chromosomen: Telomere und Telomerase
Cech, T. R. (2000) · Angewandte Chemie · doi:10.1002/(sici)1521-3757(20000103)112:1<157::aid-ange157>3.0.co;2-r · Cited by 30
Kamradt, J., Drosse, C., Kalkbrenner, S., Rohde, V., Lensch, R., Lehmann, J., Fixemer, T., Bonkhoff, H., Stöeckle, M., & Wullich, B. (2003) · Laboratory Investigation · doi:10.1097/01.lab.0000069035.85309.30 · Cited by 31
“These mechanisms, referred to as alternate lengthening of telomeres, have not been elucidated yet (Bryan et al, 1997).”
BackgroundHistone deacetylase inhibitors and retinoic acids inhibit growth of human neuroblastoma in vitro
Coffey, D. C., Kutko, M. C., Glick, R. D., Swendeman, S. L., Butler, L. M., Rifkind, R. A., Marks, P. A., Richon, V. M., & LaQuaglia, M. P. (2000) · Medical and Pediatric Oncology · doi:10.1002/1096-911x(20001201)35:6<577::aid-mpo18>3.0.co;2-3 · Cited by 62
Telomere biology of trypanosomatids: beginning to answer some questions
Lira, C. B. B., Giardini, M. A., Siqueira-Neto, J. L., Conte, F. F., & Cano, M. I. N. (2007) · Trends in Parasitology · doi:10.1016/j.pt.2007.06.005 · Cited by 31
Telomerase activity and telomere length in human hepatocellular carcinoma
Huang, G., Lee, H.-S., Chen, C.-H., Chiou, L., Lin, Y., Lee, C.-Z., Chen, D., & Sheu, J. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00237-8 · Cited by 29
Fujita, T., Yuno, M., Okuzaki, D., Ohki, R., & Fujii, H. (2015) · PLoS ONE · doi:10.1371/journal.pone.0123387 · Cited by 36
“Telomeric repeats are maintained by the action of telomerase, which comprises a protein component named telomerase reverse transcriptase (TERT), and an RNA component named Terc [20, 21].”
BackgroundMa, L., Wang, X., Duan, M., Liu, L., Shi, J.-Y., Dong, L., Yang, L., Wang, Z., Ding, Z., Ke, A., et al. (2017) · The Journal of Pathology · doi:10.1002/path.4961 · Cited by 30
“Since telomere lengths are maintained by reactivation of telomerase in the majority of human malignancies [27], we also detected the mRNA level of telomerase by real-time RT-PCR in 64 HCC patients and found a positive correlation between TERT mRNA level and RTL (p< 0.”
BackgroundGüneş, Ç., Avila, A. I., & Rudolph, K. L. (2017) · Differentiation · doi:10.1016/j.diff.2017.12.004 · Cited by 31
Alternative Lengthening of Telomeres in Pediatric Cancer: Mechanisms to Therapies
Kent, T., Gracias, D., Shepherd, S., & Clynes, D. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01518 · Cited by 31
“These cancers, collectively, are referred to as the Alternative Lengthening of Telomeres (ALT) cancers (12).”
BackgroundGrandin, N., & Charbonneau, M. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00817-08 · Cited by 30
“In a subset of human cancers, mainly soft tissue sarcomas, osteosarcomas, and astrocytomas, tumor cells rely on an alternative pathway of telomere maintenance, the ALT (alternative lengthening of telomeres) pathway, for proliferation (10, 30).”
BackgroundPendino, F., Sahraoui, T., Lanotte, M., & Ségal-Bendirdjian, E. (2002) · Leukemia · doi:10.1038/sj.leu.2402470 · Cited by 31
Targeting telomeres and telomerase
Sun, D., & Hurley, L. H. (2001) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(01)40443-5 · Cited by 33
The end replication problem: More than one solution
Lundblad, V. (1997) · Nature Medicine · doi:10.1038/nm1197-1198 · Cited by 34
Telomerase in cancer: Clinical applications
Urquidi, V., Tarin, D., & Goodison, S. (1998) · Annals of Medicine · doi:10.3109/07853899809002483 · Cited by 31
Alternative lengthening of telomeres (ALT) cells viability is dependent on C-rich telomeric RNAs
Rosso, I., Jones-Weinert, C. W., Rossiello, F., Cabrini, M., Brambillasca, S., Muñoz‐Sagredo, L., Lavagnino, Z., Martini, E., Tedone, E., Garrè, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42831-0 · Cited by 33
“Due to this recombinogenic nature of ALT telomeres, they are often long and heterogeneous in length 21 .”
BackgroundTelomere length variation: A potential new telomere biomarker for lung cancer risk
Sun, B., Wang, Y., Kota, K. K., Shi, Y., Motlak, S., Makambi, K. H., Loffredo, C. A., Shields, P. G., Yang, Q., Harris, C. C., et al. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.03.011 · Cited by 30
“However, almost all cancer cells have found ways to escape from the normal replicative limitation through maintaining their telomeres, either by up-regulation of telomerase (11) or by an alternative lengthening of telomeres (ALT) mechanism (12, 13).”
BackgroundHall, A. C., Ostrowski, L., Pietrobon, V., & Mekhail, K. (2017) · Nucleus · doi:10.1080/19491034.2017.1292193 · Cited by 31
Telomere Dysfunction in Chronic Lymphocytic Leukemia
Jebaraj, B. M. C., & Stilgenbauer, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.612665 · Cited by 29
“In addition, certain neoplasms undergo telomeraseindependent alternative lengthening of telomeres (ALT), a recombination dependent pathway that utilizes telomeres of adjacent chromosomes as template for elongation and maintenance of critical telomere length (7, 8).”
BackgroundChen, Y., Dagg, R. A., Zhang, Y., Lee, J. H. Y., Lu, R., Rotta, N. M. L., Sampl, S., Korkut-Demirbaş, M., Holzmann, K., Lau, L. M. S., et al. (2021) · Cancers · doi:10.3390/cancers13215369 · Cited by 33
“Another characteristic of ALT is heterogeneous telomere lengths ranging from (telomere) signal-free chromosome ends to abnormally long telomeres [2,4,7,8].”
BackgroundSelf-citationGonzález, J. B., García-Expósito, L., Galaviz, P., Lynskey, M. L., Allen, J. A. M., Hoang, S. M., Watkins, S. C., Pickett, H. A., & O’Sullivan, R. J. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110088 · Cited by 29
“These engage a homology-directed repair (HDR) mechanism of telomere length maintenance, termed alternative lengthening of telomeres (ALT) (Bryan et al., 1997).”
BackgroundSugimoto, M. (2013) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2013.1592 · Cited by 29
“We hypothesized (28) that an alternative pathway is involved in maintaining telomeres (29) in order to maintain telomere length in normal and WS LCLs that have relatively long life spans (28) compared with normal fibroblasts (30).”
Telomere Reprogramming and Maintenance in Porcine iPS Cells
Ji, G., Ruan, W., Liu, K., Wang, F., Sakellariou, D., Chen, J., Yang, Y., Okuka, M., Han, J., Liu, Z., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074202 · Cited by 29
“In addition to telomerase, ALT also plays an important role in telomere length maintenance [59,60] and may partially compensate for telomere shortening that otherwise occurs due to telomerase insufficiency.”
BackgroundGocha, A. R. S., Harris, J. M., & Groden, J. L. (2012) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2012.11.006 · Cited by 33
“ALT cells are characterized by the ability to maintain telomeres in the absence of telomerase and by highly heterogeneous [10, 15, 16] telomere lengths [17, 18].”
Telomerase enzymatic component hTERT shortens long telomeres in human cells
Zheng, Y., Zhang, F., Sun, B., Du, J., Sun, C., Yuan, J., Wang, Y., Tao, L., Kota, K. K., Liu, X., et al. (2014) · Cell Cycle · doi:10.4161/cc.28705 · Cited by 32
Metadata
- Authors
- Bryan, T. M., Englezou, A., Dalla-Pozza, L., Dunham, M. A., & Reddel, R. R.
- Affiliations
- Children's Medical Research Institute (AU)
- Corresponding author
- Reddel, Roger R.
- Venue
- Nature Medicine
- Published
- 1997-11
- Volume
- 3
- Issue
- 11
- Pages
- 1271-1274
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2013073993
- Cited by
- 1,292
- References
- 39
- Citations by year
- 2026: 19 · 2025: 41 · 2024: 37 · 2023: 48 · 2022: 31 · 2021: 34 · 2020: 44 · 2019: 52 · 2018: 27 · 2017: 54 · 2016: 35 · 2015: 52 · 2014: 33 · 2013: 52 · 2012: 39
- FWCI
- 27.26
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA and Nucleic Acid Chemistry
- Keywords
- alternative lengthening of telomeres, telomere maintenance, telomerase, tumor-derived cell lines, cell immortalization, telomerase inhibitors, cancer therapy, telomere loss
- MeSH terms
- Adult, DNA Nucleotidyltransferases, Humans, Neoplasms, Tumor Cells, Cultured, Deoxyribonucleases, Type II Site-Specific, Telomere, Telomerase
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.